Capital Research Global Investors Raises Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Capital Research Global Investors lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 32.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,968,513 shares of the biopharmaceutical company's stock after purchasing an additional 1,724,610 shares during the quarter. Capital Research Global Investors owned about 5.40% of Alnylam Pharmaceuticals worth $1,639,767,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ALNY. Capital World Investors raised its stake in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after acquiring an additional 92,101 shares during the period. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock valued at $2,996,296,000 after purchasing an additional 98,303 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $1,045,822,000. Norges Bank bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $577,941,000. Finally, Geode Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 2,206,800 shares of the biopharmaceutical company's stock valued at $518,367,000 after buying an additional 59,597 shares during the period. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $234.56 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm has a market cap of $30.51 billion, a P/E ratio of -108.09 and a beta of 0.30. The business's 50 day moving average price is $249.14 and its 200 day moving average price is $257.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares of the company's stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research analyst reports. HC Wainwright reissued a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Citigroup increased their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Chardan Capital reiterated a "buy" rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Finally, Sanford C. Bernstein lowered their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $315.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.